Connect with us

Bussiness

Jim Cramer says Eli Lilly isn’t a ‘one trick pony’ after FDA advisers endorse its Alzheimer’s drug

Published

on

Jim Cramer says Eli Lilly isn’t a ‘one trick pony’ after FDA advisers endorse its Alzheimer’s drug

CNBC’s Jim Cramer on Tuesday explained why he continues to be bullish about pharmaceutical giant Eli Lilly. Continually confident about Eli Lilly because of the enormous success of its weight loss and diabetes drugs, he said the company’s new Alzheimer’s treatment has the potential to further boost business.

“Right now, Eli Lilly’s an $823 billion behemoth, and I truly believe it’s ultimately headed to a trillion dollar valuation, mostly fueled by the GLP-1 revolution,” Cramer said. “But yesterday we got still more proof that Lilly’s not merely a one-trick pony.”

Continue Reading